Abstract:The growth factor receptor-bound protein 2 (Grb2) is an SH2 domain-containing docking module that represents an attractive target for anticancer therapeutic intervention. To improve the potency and bioavailability of the Grb2-SH2 inhibitors, the chiral alpha-methyl-alpha-carboxyalkyl amino acid [(alpha-Me)Aa] was designed to cover dual structural and functional features separately contributed by 1-aminocyclohexanecarboxylic acid (Ac6c) and alpha-aminoadipic acid (Adi) in position Y + 1. The enantiopure L(or D)-(alpha-Me)Aa bearing various chain length carboxylalkyl side chain was conveniently synthesized by an optimized oxazolidinone methodology. The incorporation of (S)-(alpha-Me)Aa into the non-pTyr-containing peptide framework with a 5-amino acid sequence binding motif of X(-2)-Leu-(3'-substituted-Tyr)(0) -X(+1)-Asn really improved the inhibitory activity, affording potent (R)-sulfoxide-bridged cyclic and an open-chain series of pentapeptide inhibitors of Grb2-SH2 domain (IC(50) = 1.1-5.8 mu M). More significantly, these (alpha-Me)Aa incorporated peptide inhibitors showed excellent activities in inhibiting the growth of erbB2-dependent MDA-MB-453 tumor cell lines with low micromolar IC(50) values, owing to the reduced peptidic nature and absence of pTyr or pTyr mimetics.

Synthesis and SAR Study of Novel Peptide Aldehydes As Inhibitors of 20S Proteasome

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study

Exploration of Novel Macrocyclic Dipeptide N-benzyl Amides As Proteasome Inhibitors.

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Novel CADD-based Peptidyl Vinyl Ester Derivatives As Potential Proteasome Inhibitors

Design and Synthesis of A Novel Class of Furan-Based Molecules As Potential 20s Proteasome Inhibitors

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Structure-Based Design Of Tripeptide Derivatives Of α-Aminoalkylphosphonate Esters For Prostate-Specific Antigen Inhibition

Synthesis and Preliminary Evaluation of Peptidomimetic Inhibitors of Human Beta-Secretase

Study of the Prodrugs of Peptide Aldehydes As Proteasome Inhibitors

Synthesis and Biological Activity of Peptide Proline-Boronic Acids As Proteasome Inhibitors

Design, Synthesis and Biological Evaluation of Tripeptide Boronic Acid Proteasome Inhibitors

Design, Synthesis and Evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide Derivatives As BACE-1 Inhibitors

Protein Degradation via CRL4 CRBN Ubiquitin Ligase: Discovery and Structure-Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1.

A Potent and Selective Inhibitor for the UBLCP1 Proteasome Phosphatase.

New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment

Design, synthesis and biological assay of novel tripeptidic tetrazoles as inhibitors of 20S proteasome

Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment

Synthesis and Utilization of Chiral α-Methylated α-Amino Acids with a Carboxyalkyl Side Chain in the Design of Novel Grb2-SH2 Peptide Inhibitors Free of Phosphotyrosine

Searching for the Multi-Target-Directed Ligands Against Alzheimer'S Disease: Discovery of Quinoxaline-Based Hybrid Compounds with Ache, H3r and Bace 1 Inhibitory Activities